Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining of human kidney 2 mm array spot. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is see as a staining to include the thin and distal microtubules.)
Rabbit anti-Human Phosphoinositide 3 Kinase, p110 beta Polyclonal Antibody | anti-PI3Kbeta antibody
Phosphoinositide 3 Kinase, p110 beta (DKFZp779K1237, MGC133043, p110beta, Phosphatidylinositol 3 Kinase Catalytic beta Polypeptide, Phosphatidylinositol-4,5-bisphosphate 3-kinase Catalytic Subunit beta Isoform, Phosphoinositide 3 Kinase Catalytic beta Pol
ELISA: 0.5ng/well
WB: 0.05-0.1ug/ml
Applications are based on unconjugated antibody.
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining of human kidney 2 mm array spot. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is see as a staining to include the thin and distal microtubules.)
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining of human kidney 2 mm array spot. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is see as a staining to include the thin and distal microtubules.)
Immunocytochemistry (ICC)
(Confocal Immunocytochemistry Analysis: HeLa cells were fixed, permeablized, and stained with MBS620204 (Cy3, red), DAPI (blue, nuclei), and Phalloidin-AlexaFluor488 (actin, green). Figure on the left has the DAPI filter off.)
Immunocytochemistry (ICC)
(Confocal Immunocytochemistry Analysis: HeLa cells were fixed, permeablized, and stained with MBS620204 (Cy3, red), DAPI (blue, nuclei), and Phalloidin-AlexaFluor488 (actin, green). Figure on the left has the DAPI filter off.)
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining in colorectal carcinoma. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is seeing as a plasma membrane staining pattern.)
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining in colorectal carcinoma. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is seeing as a plasma membrane staining pattern.)
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining of human skeletal muscle. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is seeing as a staining pattern of cross banding striated muscle fibers.)
Immunocytochemistry (ICC)
(Immunocytochemistry: PI3-Kinase, p110b staining of human skeletal muscle. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. MBS620204 diluted to 1:100, IHC-Select Detection with HRP-DAB. Immunoreactivity is seeing as a staining pattern of cross banding striated muscle fibers.)
Immunoprecipitation (IP)
(Immunoprecipitation: 10ug of MBS620204 was used to immunoprecipitate from 500ug of Jurkat whole cell lysate. The antibody was collected on Protein A beads and eluted with sample buffer. 5uL of Jurkat whole cell lysate was then resolved via SDS-PAGE, transferred to PVDF and probed with 0.5ug ofMBS620204. Proteins were visualized using anti-rabbit-HRP conjugate and an ECL system.)
Immunoprecipitation (IP)
(Immunoprecipitation: 10ug of MBS620204 was used to immunoprecipitate from 500ug of Jurkat whole cell lysate. The antibody was collected on Protein A beads and eluted with sample buffer. 5uL of Jurkat whole cell lysate was then resolved via SDS-PAGE, transferred to PVDF and probed with 0.5ug ofMBS620204. Proteins were visualized using anti-rabbit-HRP conjugate and an ECL system.)
Western Blot (WB)
(Western Blot Analysis: Representative lot data. Lysate from HEK-293 cells was resolved by electrophoresis, transferred to PVDF and probed with anti-PI3 Kinase, p110beta (0.05 ug/mL). Proteins were visualized using donkey anti-rabbit secondary antibody conjugated to HRP and chemiluminescence detection. Arrow indicates PI3 Kinase, p110beta (~110kD).)
Western Blot (WB)
(Western Blot Analysis: Representative lot data. Lysate from HEK-293 cells was resolved by electrophoresis, transferred to PVDF and probed with anti-PI3 Kinase, p110beta (0.05 ug/mL). Proteins were visualized using donkey anti-rabbit secondary antibody conjugated to HRP and chemiluminescence detection. Arrow indicates PI3 Kinase, p110beta (~110kD).)
NCBI and Uniprot Product Information
NCBI Description
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. [provided by RefSeq, Jul 2008]
Uniprot Description
PIK3CA: Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1- AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1 in nuclear extracts. Interacts with RUFY3. Interacts with RASD2. Interacts with APPL1. Interacts with HRAS1 and KRAS. Interaction with HRAS1/KRAS is required for PI3K pathway signaling and cell proliferation stimulated by EGF and FGF2. Belongs to the PI3/PI4-kinase family.
Protein type: Motility/polarity/chemotaxis; Oncoprotein; EC 2.7.11.1; EC 2.7.1.153; Kinase, lipid; Carbohydrate Metabolism - inositol phosphate
Chromosomal Location of Human Ortholog: 3q26.3
Cellular Component: lamellipodium; plasma membrane; phosphoinositide 3-kinase complex; cytosol
Molecular Function: protein serine/threonine kinase activity; protein binding; phosphatidylinositol-4,5-bisphosphate 3-kinase activity; insulin receptor substrate binding; 1-phosphatidylinositol-3-kinase activity; kinase activity; protein kinase activator activity; ATP binding; phosphatidylinositol-4-phosphate 3-kinase activity; phosphoinositide 3-kinase activity
Biological Process: epidermal growth factor receptor signaling pathway; platelet activation; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; nerve growth factor receptor signaling pathway; regulation of multicellular organism growth; glucose metabolic process; positive regulation of peptidyl-serine phosphorylation; T cell receptor signaling pathway; protein amino acid phosphorylation; vasculature development; phosphoinositide phosphorylation; positive regulation of protein kinase activity; phospholipid metabolic process; T cell costimulation; phosphatidylinositol biosynthetic process; protein kinase B signaling cascade; insulin receptor signaling pathway; innate immune response; endothelial cell migration; negative regulation of neuron apoptosis; angiogenesis; blood coagulation; vascular endothelial growth factor receptor signaling pathway; leukocyte migration; cardiac muscle contraction
Disease: Cowden Syndrome 5; Gastric Cancer; Keratosis, Seborrheic; Breast Cancer; Lung Cancer; Ovarian Cancer; Congenital Lipomatous Overgrowth, Vascular Malformations, And Epidermal Nevi; Colorectal Cancer; Megalencephaly-capillary Malformation-polymicrogyria Syndrome; Hepatocellular Carcinoma; Nevus, Epidermal
Research Articles on PI3Kbeta
Similar Products
Product Notes
The PI3Kbeta pik3ca (Catalog #AAA6493198) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Phosphoinositide 3 Kinase, p110 beta (DKFZp779K1237, MGC133043, p110beta, Phosphatidylinositol 3 Kinase Catalytic beta Polypeptide, Phosphatidylinositol-4,5-bisphosphate 3-kinase Catalytic Subunit beta Isoform, Phosphoinositide 3 Kinase Catalytic beta Pol reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's Phosphoinositide 3 Kinase, p110 beta can be used in a range of immunoassay formats including, but not limited to, Immunocytochemistry (ICC), ELISA (EIA), Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC). ICC: 1:100 ELISA: 0.5ng/well WB: 0.05-0.1ug/ml Applications are based on unconjugated antibody. Researchers should empirically determine the suitability of the PI3Kbeta pik3ca for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Phosphoinositide 3 Kinase, p110 beta, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
